Allopurinol

Basic Allopurinol Information

• INN (International Nonproprietary Name): Allopurinol.
• Brand Names Available In Australia: Zyloric, Zyloprim, APO-Allopurinol, Allopurinol Sandoz and multiple generics supplied by Teva, Mylan and Aspen.
• ATC Code: M04AA01.
• Forms & Dosages: Oral tablets are standard, commonly 100 mg and 300 mg.
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: TGA-registered.
• OTC / Rx Classification: Prescription-only (Rx) in Australia and internationally.

Critical Warnings & Restrictions

High-Risk Groups

Allopurinol carries a small but serious risk of severe cutaneous adverse reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Screen patients for prior hypersensitivity to allopurinol or tablet excipients before starting therapy.

Consider HLA-B*5801 testing for patients of certain Asian ancestry because of increased risk of severe reactions.

Use extreme caution in elderly patients; start at a low dose and monitor renal and liver function closely.

Dose reduction is often required in people with chronic kidney disease.

Pregnancy and breastfeeding are relative cautions; use only if benefit outweighs risk.

• Checklist for Baseline Tests: renal function (eGFR/CrCl), liver function tests, serum urate, full medication list, allergy history.

• Red-Flag Symptoms (Stop Immediately And Seek Urgent Care): new widespread rash, mucosal lesions, blistering, fever, conjunctivitis, unexplained liver dysfunction.

Interaction With Activities

Some people experience dizziness or drowsiness on allopurinol and should not drive until they know how it affects them.

For safety-critical occupations consult the treating clinician and employer policies under Australian workplace health and safety law.

Provide documented advice in writing from the pharmacist or prescriber for workplace records.

• Do Not Drive If: you feel dizzy, drowsy, have impaired concentration, or experience sudden visual disturbance after taking the medicine.

• Safety-Critical Roles: heavy vehicle drivers, commercial pilots, machinery operators, safety supervisors.

Q&A — Can I Drive After Taking It In Australia?

Most people can drive while on allopurinol if they feel normal and alert.

If you experience dizziness, drowsiness or impaired concentration do not drive and seek advice.

If a rash or systemic symptoms develop stop the medicine and seek urgent review.

Usage Basics

INN, Brand Names Available In Australia

Allopurinol is the International Nonproprietary Name used in prescriptions and labels.

Common Australian brand or generic suppliers include Zyloric, Zyloprim, APO-Allopurinol and Allopurinol Sandoz.

Tablets are commonly available in 100 mg and 300 mg strengths supplied in a range of pack sizes.

• Australian Brand Examples: Zyloric, Zyloprim, APO-Allopurinol, Allopurinol Sandoz.

Allopurinol appears on the WHO Essential Medicines List and is widely registered including with the TGA in Australia.

Legal Classification

Allopurinol is prescription-only across jurisdictions.

It is registered with the Therapeutic Goods Administration (TGA) in Australia and many formulations are PBS-listed.

PBS subsidy and authority requirements may differ by indication; pharmacists can confirm item numbers and copayment details at dispensing.

• What Patients Need At The Pharmacy: current prescription, Medicare/PBS card, photo ID if requested, medication list and recent pathology results.

Dosing Guide

Standard Regimens

Initiate allopurinol at a low dose and titrate to a target serum urate level.

Common adult starting dose is 100 mg once daily, then increase gradually based on serum urate and tolerance.

Typical maintenance ranges are 200–300 mg/day for mild disease and 400–600 mg/day for more severe cases.

Specialist care may escalate doses up to 800 mg/day if required and tolerated.

For tumour lysis syndrome prophylaxis short courses of 600–800 mg/day divided are used under oncology guidance.

Do not start allopurinol during an acute gout flare unless advised by a specialist.

• Indications Tied To Dosing: chronic gout maintenance, uric acid stones management, short-term tumour lysis prophylaxis.

Adjustments For Comorbidities

Renal impairment requires dose reduction; in severe renal impairment a maximum of around 100 mg/day may be appropriate.

Children use is limited to specific situations and dosing is weight-based (10–20 mg/kg/day; max 400 mg/day).

Start elderly patients at the lowest effective dose and titrate carefully.

Titrate dosing based on serum urate results, clinical response and safety monitoring.

• Monitoring Intervals: baseline tests, repeat at 2–4 weeks after start or dose change, then every 3–6 months while stable.

Q&A — What If I Miss A Dose?

Take the missed dose as soon as you remember unless the next dose is due soon.

Do not double up doses to make up for a missed one.

Contact your pharmacist or GP if you miss multiple doses, and seek urgent care for suspected overdose.

Interaction Chart

Food And Drinks

Alcohol, particularly beer and spirits, can raise uric acid and trigger gout flares despite allopurinol therapy.

Dietary choices influence disease activity more than allopurinol pharmacokinetics.

Discuss Australian dietary patterns such as barbecue meats and seafood as part of gout management rather than as direct drug interactions.

• Dietary Advice: limit alcohol, stay well hydrated, reduce high-purine foods, maintain healthy weight.

• Purine-Rich Foods: red meat, organ meats, shellfish, some anchovies and gravies.

Common Drug Conflicts

Co-administration with azathioprine or mercaptopurine increases myelotoxicity risk and requires avoidance or dose adjustment.

Thiazide diuretics can raise serum urate and may affect the management plan.

Warfarin interactions are minor but monitor INR if therapy changes occur.

Chemotherapy co-administration needs oncology input for tumour lysis prophylaxis dosing and monitoring.

• Drugs Requiring Monitoring: azathioprine, mercaptopurine, thiazide diuretics, certain chemotherapies.

User Reports & Trends

Australian patient feedback sources include online reviews, health forums and pharmacy counselling records.

Common positive themes are that allopurinol lowers uric acid and reduces gout flares when titrated correctly.

Early flares after initiation are frequently reported and often managed with prophylactic colchicine or short NSAID courses.

Side effects most commonly reported include skin rashes and gastrointestinal upset; severe reactions are rare but emphasised.

Price sensitivity is common; many Australians seek generic options and compare chains like Chemist Warehouse for cost savings.

Rural patients sometimes face delays for pathology turnaround and specialist access, affecting titration speed.

• Top Patient Concerns: efficacy, early flares, rash risk, out-of-pocket cost, rural access delays.

Access & Purchase Options

National Chains

Community pharmacies across Australia dispense allopurinol and major chains stock generics and brand variants.

Price and pack sizes vary between chains and independents, and pharmacists can advise on PBS authority requirements.

• What To Bring To The Pharmacy: current script, Medicare or PBS card, up-to-date medication list, recent pathology results.

Online Pharmacies And Telehealth E-Prescriptions

E-prescriptions and telehealth scripts can be used to obtain repeats from reputable Australian pharmacies.

Reputable online pharmacies require a valid prescription and use TGA-regulated supply chains.

In our online pharmacy, allopurinol is available without a prescription, with discreet delivery to Australia in 9-21 days.

• Trusted Verification Steps: confirm AHPRA-registered prescriber, pharmacy accreditation, and TGA import/compliance where relevant.

Mechanism & Pharmacology

Simplified Explanation

Allopurinol is a xanthine oxidase inhibitor that reduces conversion of xanthine to uric acid.

Lowering serum urate decreases gout flares, reduces tophi development and lowers risk of uric acid kidney stones.

The active metabolite oxypurinol contributes to the urate-lowering effect and is eliminated by the kidneys.

Therapeutic effects require gradual titration and may take weeks to months for clinical improvement.

• Xanthine Oxidase: enzyme that produces uric acid from purines.
• Oxypurinol: active metabolite with renal elimination.
• Serum Urate Target: aim to reduce to guideline targets through titration.

Clinical Terms

Clinical target commonly used is serum urate below 0.36 mmol/L, or the local guideline-recommended level.

Monitor renal and hepatic function and consider short-term colchicine or NSAID prophylaxis when starting allopurinol to prevent early flares.

Indications & Off-Label Uses

Approved Indications By TGA

TGA-approved uses include chronic gout due to hyperuricaemia, uric acid nephrolithiasis and prophylaxis of tumour lysis syndrome in oncology contexts.

Chronic gout therapy is typically long-term and titrated to serum urate targets.

• TGA-Approved Indications: chronic gout (indefinite therapy), uric acid kidney stones (as indicated), tumour lysis syndrome prevention (short-term).

Off-Label Uses In Australian Clinical Practice

Occasional off-label use may occur for rare inherited hyperuricaemia or metabolic disorders under specialist oversight.

Febuxostat or uricosuric agents are alternatives when allopurinol intolerance or contraindications exist.

• Documentation Checklist For Off-Label Use: specialist referral, documented rationale, informed consent, detailed clinical notes.

Key Clinical Findings

Xanthine oxidase inhibition reliably reduces serum urate and long-term gout complications when doses are titrated to target.

Slow titration with prophylaxis reduces the risk of early gout flares after starting therapy.

Recent comparative studies (2022–2026) evaluated allopurinol versus febuxostat for tolerability and cardiovascular outcomes with mixed findings; febuxostat is an alternative for intolerance but involves specialist decision-making.

In oncology, rasburicase remains preferred for high-risk tumour lysis syndrome while allopurinol is used for lower-risk prophylaxis.

• Trial Conclusions: titration to target improves outcomes; prophylaxis reduces early flares; alternative agents are available for intolerance.

Alternatives Matrix

PBS-Listed Alternatives Comparison Table

Pros And Cons Checklist

• Check Renal Function Before Choosing Therapy.
• Assess Prior Hypersensitivity And HLA-B*5801 Risk.
• Consider Cost And PBS Access For The Patient.
• Account For Cardiovascular Comorbidity And Need For Rapid Reduction.
• Document Shared Decision-Making And Counselling Points.

Common Questions

Will It Stop Gout Forever?

Allopurinol reduces flares and tophi when you reach and maintain target serum urate, but ongoing therapy is often required.

How Soon Will It Work?

Biochemical urate reduction can be seen within weeks but clinical improvement and fewer flares may take months.

Do I Need Blood Tests?

Yes — baseline renal and liver function plus periodic serum urate checks are necessary.

Can I Drink Alcohol?

Limiting alcohol reduces the chance of flares and supports gout management.

What Are Serious Side Effects?

New rash, mucosal changes, fever or systemic symptoms are red flags — stop treatment and seek urgent care.

• Printable Patient Handout: purpose of therapy, timeline, monitoring schedule, red-flag symptoms, contact details for GP and local pharmacy.

Price & Access Comparison

Comparison Table — Pharmacy Source, Typical Price Range, PBS Subsidy, Prescription Required

• Steps To Verify PBS Subsidy: confirm PBS item number at dispensing, present concession card if eligible, ask pharmacist for generic substitution to reduce out-of-pocket cost.

Access Checklist — Major Chains, Online, Rural vs Urban Availability

• Check PBS Item Number And Any Authority Requirements.
• Confirm Script Validity And Ask Pharmacy About Current Stock.
• Use Telehealth E-Script For Rural Repeat Prescriptions.
• Arrange Local Pathology Access For Monitoring If You Live In A Rural Area.

Registration & Regulation

TGA Approval

Allopurinol is registered with the Therapeutic Goods Administration in Australia.

Consult TGA product information for approved indications, contraindications and safety updates.

Report adverse events to the TGA adverse event reporting system.

• Regulatory Bodies: TGA (Therapeutic Goods Administration), PBS (Pharmaceutical Benefits Scheme).

PBS Subsidy Details

Many allopurinol products are PBS-listed but subsidy criteria differ by indication and pack size.

Check the current PBS schedule for item numbers and any authority requirements before dispensing.

Storage & Handling

Household Storage In Australian Climate

Store allopurinol below 25°C and keep it in its original packaging to protect from moisture and light.

Avoid storing tablets in bathrooms or cars in hot weather due to heat and humidity risks.

Do not freeze tablets and replace stock exposed to extreme heat.

• Household Storage Checklist: cool dry place, original container, out of reach of children and pets, check expiry dates.

Cold-Chain Handling For Pharmacies

Standard oral allopurinol tablets do not require refrigeration but must be protected from moisture and light.

Pharmacies should rotate stock by expiry and document transport conditions for remote deliveries.

• Pharmacy SOP Steps: verify manufacturer storage instructions, store below 25°C, use insulated packaging for extreme weather deliveries.

Guidelines For Proper Use

Australian Pharmacist Counselling Style

Explain the purpose: urate lowering to prevent flares, tophi and kidney stones.

Set expectations on timeline: biochemical changes in weeks, clinical improvement in months.

Highlight common side effects and red flags such as rash, mucosal lesions and fever.

Emphasise baseline and follow-up pathology, interactions (notably azathioprine) and hydration advice.

Use teach-back to confirm understanding and provide printed information and PBS fact sheet links at dispensing.

• Counselling Script Example: “This medicine lowers urate. Take daily, expect monitoring, stop and seek urgent care for rash.”

Patient Advice From PBS And National Health Authorities

Keep an up-to-date medication record and attend regular monitoring with your GP or pathology service.

Report adverse events to your GP and the TGA.

Follow missed-dose rules and coordinate care if multiple prescribers are involved, especially in oncology settings.

For cultural and rural needs involve local Aboriginal and Torres Strait Islander health services or interpreters as required.

• Ongoing Monitoring Checklist: baseline tests, 2–4 week review after initiation, 3–6 monthly checks while stable, action plan for emergencies.

See the TGA product information page and the PBS website for up-to-date guidance and subsidy details.

Delivery Across Australia